Drugs / 18F-FAPI
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05691894 | Nov 2022 → Nov 2023 | cancer | Affiliated Hospital of Jiangnan University | Unknown | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT05810324 | Jul 2022 → Jul 2024 | cancer | Jilin University | Unknown | No outcome recorded |
| — | NCT05884463 | Apr 2021 → Feb 2023 | pancreatic adenocarcinoma | Zhejiang University | Completed | No outcome recorded |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-01-15 | SOFIE | SOFIE network expands production of 18F-FAPI-74 sofie.com ↗ |
| 2023-05-12 | SOFIE | First Patient Imaged in SOFIE’s 18F-FAPI Phase 2 trial sofie.com ↗ |
| 2022-11-29 | SOFIE | SOFIE granted IND for 18F-FAPI in Phase 2 study sofie.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18F-FAPI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05884463 ↗ |
| Modality | Diagnostic / imaging agent | “tracer targeting FAP PET Imaging” NCT05691894 ↗ |
| Route | Intravenous | “single intravenous injection of 18F-FAPI” NCT05810324 ↗ |
| Target | FAP | “tracer targeting FAP PET Imaging” NCT05691894 ↗ |